A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Experts have hailed the lecanemab as 'beginning of the end' for Alzheimer's after the drug was found to slow cognitive decline by more than a quarter in clinical trials in America, Europe and Asia.

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

How does lecanemab work? Lecanemab targets a protein called amyloid. The importance of this protein in the development of Alzheimer’s disease was discovered by Alzheimer’s Society funded research led ...

The health ministry on Monday granted full approval to lecanemab, the much-hyped drug for Alzheimer's disease, but experts point out there are big challenges ahead, particularly on how to control ...

Lecanemab, also known as Leqembi, has made headlines as the first drug ever approved in the UK by the MHRA that can slow down early-stage Alzheimer’s disease, but it has not been recommended for use ...

Lecanemab, developed by Eisai and Biogen Inc, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of early-stage Alzheimer’s patients.

Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).